目的 系统评价18F-FDOPA与18F-FDG PET/CT显像在脑肿瘤诊断中的临床价值。方法 采用Meta分析与直接比较方法。使用计算机检索中国期刊全文数据库、中文科技期刊数据库、万方数据库、中国生物医学文献数据库、PubMed、Embase、The Cochrane Library,从建库至2016年10月,搜索直接比较18F-FDOPA与18F-FDG PET/CT诊断脑肿瘤的诊断性试验。用Meta-Disc1.4软件进行分析,计算两种不同显像剂的合并敏感度(sensitivity,SEN)、合并特异度(specificity, SPE)、合并阳性似然比(positive likelihood ratio, +LR)、合并阴性似然比(negative likelihood ratio, -LR)、诊断优势比(diagnostic odds ratio, DOR),并绘制综合受试者工作特征曲线计算曲线下面积(area under curve, AUC)与Q*值。结果 最终共纳入4篇文章,Meta分析结果显示,18F-FDOPA PET/CT对脑肿瘤诊断的合并SEN为0.97(95%CI=0.90～1.00),SPE为0.67(95%CI=0.45～0.84),+LR为2.31(95%CI=1.40～3.81),-LR为0.07(95%CI=0.02～0.24),DOR为39.72(95%CI=8.94～176.48),AUC为0.9725,Q*为0.9239。18F-FDG PET/CT对脑肿瘤诊断的合并SEN为0.51(95%CI=0.39～0.63),SPE为0.75(95%CI=0.53～0.90,+LR为1.59(95%CI=0.70～3.61),-LR为0.63(95%CI=0.47～0.86),DOR为2.55(95%CI=0.82～7.92),AUC为0.5848,Q*为0.5638。结论 18F-FDOPA PET/CT显像诊断脑肿瘤的敏感性比18F-FDG高,对脑肿瘤具有良好的诊断价值,可作为脑肿瘤诊断的方法之一。
Abstract
Objective To compare the diagnostic value of 18F-FDOPA and 18F-FDG PET/CT scan in patients with brain tumors by Meta analysis.Methods Data on diagnostic experiments related to the diagnostic value of 18F-FDOPA and 18F-FDG PET/CT scan for brain tumors was retrieved from CNKI, CSJD, WanFang Database, CBM, PubMed, Embase, Cochrane Library by October 2016. The diagnostic value of 18F-FDOPA and 18F-FDG PET/CT scan for brain tumors was compared. Meta-DiSc 1.4 software was used to analyze the pooled sensitivity (SEN), specificity (SPE),positive likelihood ratio (+LR), negative likelihood ratio (-LR), diagnostic odds ratio (DOR) under curve (AUC) the two different imaging agents.Results A total of four studies met the inclusion criteria. According to the results of 18F-FDOPA in diagnosis of brain tumors, the pooled SEN was 0.97(95%CI=0.90-1.00), SPE 0.67(95%CI=0.45-0.84),2.31(95%CI=1.40-3.81),0.07(95%CI=0.02-0.24), DOR 39.72(95%CI=8.94-176.48), SROC AUC 0.9725,and Q* value. According to the diagnostic results of 18F-FD, the pooled SEN was 0.51(95%CI=0.39-0.63),0.75(95%CI=0.53-0.90),2.31(95%CI=0.70-3.61),0.07(95%CI=0.47-0.86),DOR 2.55(95%CI=0.82-7.92), SROC AUC 0.5848,and Q* value was 0.5638.Conclusions 18F-FDOPA PET/CT imaging is more sensitive than 18F-FDG in the diagnosis of brain tumors.18F-FDOPA is of high diagnostic value for brain tumors and can be used as a reliable diagnostic method of brain tumors.
关键词
脑肿瘤 /
PET/CT /
18F-FDOPA /
18F-FDG
Key words
brain tumor /
PET/CT /
18F-FDOPA /
18F-FDG
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Ostrom Q T, Gittleman H, Farah P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010[J]. Neuro Oncol, 2013, 15 (Sup 2):1-56.
[2] Li Z, Yu Y, Zhang H, et al. A meta-analysis comparing 18F-FLT PET with 18F-FDG PET for assessment of brain tumor recurrence[J]. Nucl Med Commun, 2015, 36(7):695-701.
[3] 李 云,嵇 辉,张燕齐,等. (18)F-FDG PET/CT显像寻找肿瘤原发灶25例[J]. 武警医学, 2012, 23(8):710-711.
[4] Okochi Y, Nihashi T, Fujii M, et al. Clinical use of (11)C-methionine and (18)F-FDG-PET for germinoma in central nervous system[J]. Ann Nucl Med, 2014, 28(2):94-102.
[5] Van Waarde A ,Elsinga P H. Proliferation markers for the differential diagnosis of tumor and inflammation[J]. Curr Pharm Des, 2008, 14(31):3326-3339.
[6] Zhao C, Zhang Y, Wang J. A meta-analysis on the diagnostic performance of (18)F-FDG and (11)C-methionine PET for differentiating brain tumors[J]. AJNR Am J Neuroradiol, 2014, 35(6):1058-1065.
[7] Calabria F,Cascini GL. Current status of 18F-DOPA PET imaging in the detection of brain tumor recurrence[J]. Hell J Nucl Med, 2014, 18(2):152-156.
[8] Spence A M, Mankoff D A, Muzi M. Positron emission tomography imaging of brain tumors[J]. Neuroimaging Clin N Am, 2003, 13(4):717-739.
[9] Glaudemans A W, Enting R H, Heesters M A, et al. Value of 11C-methionine PET in imaging brain tumours and metastases[J]. Eur J Nucl Med Mol Imaging, 2013, 40(4):615-635.
[10] Minn H, Kauhanen S, Seppanen M, et al. 18F-FDOPA: a multiple-target molecule[J]. J Nucl Med, 2009, 50(12):1915-1918.
[11] Whiting P, Rutjes A W, Reitsma J B, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews[J]. BMC Med Res Methodol, 2003, 3(1):25.
[12] 张 俊,徐志伟,李 克. 诊断性试验Meta分析的效应指标评价[J]. 中国循证医学杂志, 2013, 13(7):890-895.
[13] Chen W, Silverman D H, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy[J]. J Nucl Med, 2006, 47(6):904-911.
[14] Jora C, Mattakarottu J J, Aniruddha P G, et al. Comparative evaluation of 18F-FDOPA, 13N-AMMONIA, 18F-FDG PET/CT and MRI in primary brain tumors - A pilot study[J]. Indian J Nucl Med, 2011, 26(2):78-81.
[15] Karunanithi S, Sharma P, Kumar A, et al. 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2013, 40(7):1025-1035.
[16] Tripathi M, Sharma R, D'Souza M, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas[J]. Clin Nucl Med, 2009, 34(12):878-883.
[17] Lawal I and Sathekge M. F-18 FDG PET/CT imaging of cardiac and vascular inflammation and infection[J]. Br Med Bull, 2016, 120(1):55-74.
[18] Struck A F, Hall L T, Kusmirek J E, et al. (18)F-DOPA PET with and without MRI fusion, a receiver operator characteristics comparison[J]. Am J Nucl Med Mol Imaging, 2012, 2(4):475-482.
[19] Scherfler C, Esterhammer R, Nocker M, et al. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease[J]. Brain, 2013, 136(10):3028-3037.
[20] Oehme L, Perick M, Beuthien-Baumann B, et al. Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with 18F-dopa brain PET in normal controls and patients with Parkinson’s disease[J]. Eur J Nucl Med Mol Imaging, 2011, 38(8):1550-1559.
[21] Fueger B J, Czernin J, Cloughesy T, et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas[J]. J Nucl Med, 2010, 51(10):1532-1538.
[22] Pafundi D H, Laack N N, Youland R S, et al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study[J]. Neuro-oncology, 2013, 15(8):1058-1067.
[23] Becherer A, Karanikas G, Szabó M, et al. Brain tumour imaging with PET: a comparison between [18F] fluorodopa and [11C] methionine[J]. Eur JNucl Med Mol Imaging, 2003,30(11):1561-1567.
基金
天津市自然科学基金(13JCYBJC22000);武警后勤学院附属医院种子基金(FYQ201601)
PDF(690 KB)
